Get the Stockscreener App
1.08
0.92%
-0.01
After Hours:
1.06
-0.02
-1.85%
Cardiol Therapeutics Inc stock is traded at $1.08, with a volume of 349.52K.
It is down -0.92% in the last 24 hours and up +3.85% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.09
Open:
$1.11
24h Volume:
349.52K
Relative Volume:
0.51
Market Cap:
$108.00M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-3.252
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+2.86%
1M Performance:
+3.85%
6M Performance:
-25.00%
1Y Performance:
-20.59%
1-Day Range:
$1.06
$1.11
1-Week Range:
$0.99
$1.12
52-Week Range:
$0.7709
$1.59
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.08 | 109.00M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Moving Average Crossover Confirms Uptrend in Dhampur Sugar Mills LimitedStock Split Announcements & Identify Safe Investments - earlytimes.in
Investors in cash trouble should check out Cardiol Therapeutics Inc (CRDL) - setenews.com
Inflation Data: Will Cardiol Therapeutics Inc CT9 stock outperform small cap peersMarket Activity Report & Fast Entry Momentum Alerts - moha.gov.vn
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Is Cardiol Therapeutics Inc. stock a defensive play in 2025July 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Cardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash Decrease - MSN
(CRDL) Market Dynamics and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
How buyback programs support Cardiol Therapeutics Inc. (CT9) stockAnalyst Upgrade & Proven Capital Preservation Tips - Newser
Why institutional investors increase stakes in Cardiol Therapeutics Inc. (CT9) stock2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
Should you sell your Cardiol Therapeutics stock? - Cantech Letter
Is Cardiol Therapeutics Inc. stock attractive for passive investorsMarket Performance Summary & Consistent Growth Stock Picks - Newser
Will Cardiol Therapeutics Inc. (CT9) stock announce special dividendWeekly Profit Recap & Daily Volume Surge Signals - Newser
Will Cardiol Therapeutics Inc. (CT9) stock issue positive guidanceJuly 2025 Action & Risk Controlled Swing Trade Alerts - Newser
What hedge fund moves indicate for Cardiol Therapeutics Inc. (CT9) stockMarket Movement Recap & Safe Entry Zone Identification - Newser
Will Cardiol Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
What RSI levels show for Cardiol Therapeutics Inc. (CT9) stock2025 Trading Recap & Consistent Growth Stock Picks - Newser
Taking the lead: Cardiol Therapeutics Inc (CRDL) - setenews.com
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 14.6%Should You Sell? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 14.6%Should You Sell? - MarketBeat
Will Cardiol Therapeutics Inc. (CT9) stock recover faster than industryJuly 2025 PreEarnings & Verified Momentum Stock Watchlist - Newser
Cardiol Therapeutics (TSE:CRDL) Shares Down 14.6%Here's What Happened - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Shares Down 17.2%Here's What Happened - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Shares Down 13.9%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 17.2%Here's What Happened - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 7.9%Here's Why - MarketBeat
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target By Investing.com - Investing.com South Africa
Is Cardiol Therapeutics Inc. (CT9) stock a top dividend aristocrat candidateGold Moves & Short-Term Trading Alerts - Newser
Why Cardiol Therapeutics Inc. stock appeals to analystsTrade Volume Report & Safe Entry Zone Identification - Newser
Cardiol Therapeutics’ (CRDL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy Recommendation - Nasdaq
CRDL.NE Interactive Stock Chart | CARDIOL THERAPEUTICS INC Stock - Yahoo! Finance Canada
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News - GuruFocus
CRDL Analyst Forecasts - Quiver Quantitative
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - TipRanks
Cardiol Therapeutics reports positive Phase II myocarditis trial results By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™ - TipRanks
CARDIOL THERAPEUTICS INC (CRDL.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics reports positive Phase II myocarditis trial results - Investing.com
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - Investing News Network
Cardiol Therapeutics (NASDAQ: CRDL) posts Phase II ARCHER myocarditis recovery data - Stock Titan
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):